Preparation can create a sense of safety, security and comfort when heading into your initial therapy appointment.

Stay updated on Beam Therapeutics Inc.'s latest advancements in Sickle Cell Disease and alpha-1 antitrypsin deficiency treatments. Click for my BEAM stock update.

You’ve heard of emotional support pets or therapy with puppies and kittens, but this US airport is doing things a bit ...

The days are getting shorter as we head into late fall, and many people start feeling down with less sunshine and cooler ...

AB-101-001 is a Phase 1a/1b double-blind, randomized, placebo-controlled clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single- ...

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of using decades-old transplant drugs alongside cutting-edge CRISPR medicines.

Exosomes are emerging as key tools in personalized and regenerative medicine, offering precise, targeted therapy with low i ...